A phase II trial of gemcitabine and carboplatin (GC) in patients with transitional cell carcinoma of the urinary tract (TCC)

Olivares, Jairo; Hyman, William; Senzer, Neil

doi:10.1200/jco.2004.22.90140.4590

Cited by 6 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However it is often not possible to use cisplatin in bladder cancer patients because of the high incidence of renal failure in this disease. Therefore other potentially inferior drugs such as carboplatin are currently used instead [5] . Oxaliplatin not only has a different mechanism of action to cisplatin, it also has different dose-limiting toxicity, and is not nephrotoxic [7,9] .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Comparison of the Platinum Analogues in Bladder Cancer Cell Lines

Powles

Perry²,

Shamash³

et al. 2007

Urol Int

View full text Add to dashboard Cite

Background: Oxaliplatin is a 3rd generation platinum analogue, which is active in a broad spectrum of tumours. Clinical trials using this drug in bladder cancer are underway, but not yet reported. There are currently no in vitro data regarding oxaliplatin in bladder cancer. Therefore, this study compares the efficacy of oxaliplatin with cisplatin and carboplatin, which are both used widely in this tumour type, in bladder cancer cell lines. Method: The efficacy of oxaliplatin, carboplatin and cisplatin were compared in 4 bladder cancer cell lines (5637, J82, HT1197 and 253J). Cell parameters including cell number, viability and apoptosis were assessed after 3 days of drug exposure. The effects of the drugs on the cell cycle were also observed. Results: Overall cisplatin was the most potent at inducing cell death (IC₅₀ 11.5–70.6 µM). Oxaliplatin was the 2nd most potent drug (IC₅₀15.2–126.3 µM) and carboplatin the least effective (IC₅₀75.4–137.8 µM). Carboplatin was significantly less potent at inducing cell death than the other two drugs in all 4 cell lines. Carboplatin was also inferior at inducing apoptosis in 3 of the 4 cell lines. All three drugs had a similar effect on the cell cycle, causing an initial G2 block. Conclusions: These data suggest that oxaliplatin is a potent agent in bladder cancer cell lines and is superior to carboplatin in this in vitro setting. It justifies the clinical studies using oxaliplatin that are underway.

show abstract

Section: Discussionmentioning

confidence: 99%

“…However, in vitro and in vivo data suggest that cisplatin is superior to carboplatin in this tumour type [3,4] . Despite this, carboplatin is still used instead of cisplatin in certain circumstances including the relatively common situation of renal failure [5,6] .…”

Section: Introductionmentioning

confidence: 99%

A Comparison of the Platinum Analogues in Bladder Cancer Cell Lines

Powles

Perry²,

Shamash³

et al. 2007

Urol Int

View full text Add to dashboard Cite

show abstract

“…The GCarbo combination has been evaluated in several observational studies and the outcome data are given in Table 3[28–37]. As a first‐line therapy gemcitabine has been administered at doses of 1200 mg/m 2 either two or three times every 3 weeks.…”

Section: Gcarbovs Methotrexate/carboplatin/vinblastine (Mcarbov)mentioning

confidence: 99%

Gemcitabine chemotherapy for the treatment of metastatic bladder carcinoma

2011

View full text Add to dashboard Cite

What's known on the subject? and What does the study add? Metastatic bladder cancer is a devastating disease that often proves fatal. Systemic chemotherapy with MVAC (methotrexate, vinblastine, adriamycin, cisplatin) has been the first choice of treatment for many years but toxicity can be severe and overall survival poor. The search for more effective drug combinations continues. Clinical data indicate that gemcitabine has activity in this disease in terms of tumour response and overall survival.

show abstract

“…A study conducted by Linardou et al with similar characteristics to Nogue-Aliguer's study showed a 36% overall response rate (ORR) with a time to progression(TTP) of 4.8 months and an OS of 7.2 months in 56 patients[20]. The other two studies included the most of patients with favorable characteristics (creatinine clearance more than 60 ml/min and good performance status) [21,22]. Patient received gemcitabine 1000–1200 mg/m 2 on days 1 and 8 of a 21-d schedule plus carboplatin AUC 5 on day 1.…”

Section: Discussionmentioning

confidence: 99%

A phase II trial of gemcitabine plus carboplatin in advanced transitional cell carcinoma of the urothelium

Zhang

Xiong

et al. 2007

BMC Cancer

View full text Add to dashboard Cite

Background: Recent studies have demonstrated the effectiveness of cisplatin-based combinations in patients with advanced transitional cell carcinoma(TCC) of the urothelium. Concern over cisplatin toxicity instigated a search for alternative regimens. The aim of the study was to evaluate the activity and tolerability of gemcitabine plus carboplatin combination as first-line treatment in patients with advanced transitional cell carcinoma of the urothelium.

show abstract

A phase II trial of gemcitabine and carboplatin (GC) in patients with transitional cell carcinoma of the urinary tract (TCC)

Cited by 6 publications

References 0 publications

A Comparison of the Platinum Analogues in Bladder Cancer Cell Lines

A Comparison of the Platinum Analogues in Bladder Cancer Cell Lines

Gemcitabine chemotherapy for the treatment of metastatic bladder carcinoma

A phase II trial of gemcitabine plus carboplatin in advanced transitional cell carcinoma of the urothelium

Contact Info

Product

Resources

About